FDA » FDA & Pescription Drugs Lawyer New York
Call For A FREE Consultation!
1 (800) 509-2335
You are here: Unnecessary radiation exposure and cancer risk common with CT scans, researchers urge FDA oversight
 
Archives by Tag 'FDA'

Unnecessary radiation exposure and cancer risk common with CT scans, researchers urge FDA oversight

By Marc J. Bern - Last updated: Wednesday, June 23, 2010

Researchers say patients are currently at risk for receiving more radiation than necessary from Computed Tomography (CT scans) and increasing cancer risk due to a current lack of standardization, monitoring and regulation of how imaging equipment is used. The editorial “Is Computed Tomography Safe?” by Rebecca Smith-Bindman, M.D. and researchers at the University of California [...]

Sen. Schumer asks FDA to release data on sunscreen ingredient linked to skin cancer

By Marc J. Bern - Last updated: Wednesday, June 16, 2010

U.S. Senator Charles E. Schumer of New York has urged the U.S Food and Drug Administration (FDA) to release their review of studies concerning cancer risk associated with retinyl palmitate, a vitamin A derivative commonly used in sunscreens, to the public. AOL News reported in May of learning through documents and interviews that the FDA [...]

FDA Warns Pfizer for Failing to Report Drug Side Effects

By Marc J. Bern - Last updated: Friday, June 11, 2010

During the course of the congressional hearing by the Committee on Oversight and Government Reform investigating the April 2010 recall of over-the-counter Johnson & Johnson/McNeil pediatric products, documents revealed that McNeil Consumer Healthcare, a unit of J&J, hired contractors to buy back defective Motrin products from store shelves secretly instead of issuing a recall. McNeil [...]

FDA Warns Pfizer for Failing to Report Drug Side Effects

By Marc J. Bern - Last updated: Thursday, June 10, 2010

The U.S. Food and Drug Administration (FDA) sent a warning letter to Pfizer, Inc. for failing to report potentially serious adverse side effects of its pharmaceutical drugs. In a May 26 letter to Jeffrey Kindler, Pfizer Chief Executive Officer, the FDA cites a number of instances in which the drug maker failed to report potentially [...]